Introduction On February 11, 2020 WHO designated the name “COVID-19” for the disease
caused by “severe acute respiratory syndrome coronavirus 2”(SARS-CoV-2), a novel virus …

Abstract Background Coronavirus disease 2019 (COVID-19) is an infectious disease
characterized by cough, fever, and fatigue and 20% of cases will develop into severe …

Aim To estimate the prevalence of both cardiometabolic and other co‐morbidities in patients
with COVID‐19, and to estimate the increased risk of severity of disease and mortality in …

Background An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan,
China; the epidemic is more widespread than initially estimated, with cases now confirmed …

Objectives Existing findings regarding the relationship between comorbidities and the
severity of coronavirus disease 2019 (COVID-19) are inconsistent and insufficient. The aim …

Background The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly
worldwide. Objective To evaluate the risk of serious adverse outcomes in patients with …

The pandemic situation with the emergence of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) from China has endangered human lives. Coronavirus …

Background and aims Currently there is limited knowledge on medical comorbidities and
COVID-19; we conducted a systematic review and meta-analysis to evaluate the impact of …

Background The novel coronavirus disease 2019 (COVID-19) has infected 1.9% of the world
population by May 2, 2021. Since most previous studies that examined risk factors for …

ABSTRACT SARS-CoV-2 has caused a worldwide pandemic that began with an outbreak of
pneumonia cases in the Hubei province of China. Knowledge of those most at risk is integral …